3rd Oligonucleotides CMC and Analytical Development Summit

Exclusively dedicated to uniting AD, QC, and CMC leaders the 3rd Oligonucleotide CMC and Analytical Development Summit is the only industry-led meeting solving your impurity, regulatory, and cost-efficiency challenges in this rapidly evolving field.

Across the three days, you'll get the chance to hear from KOLs like Ionis Pharmaceuticals, AstraZeneca, and CAMP4 Therapeutics as the present their data-driven case studies on managing quality, regulatory affairs, and cost-efficient manufacturing.

Deep dive into the major challenges of streamlining analytical tools, process development, and look towards greener chemistries to ensure global uptake of oligonucleotide drugs.

This isn't just an event, it's an investment in the future of your teams' technical capabilities. Bringing together siRNA, mRNA, ASO, oligo and oligo-conjugate developers, this definitive summit fosters comprehensive development, ensuring the resilience and longevity of this rapidly advancing modality.

Join us this August to assess the field, take back actionable insights to your team, and realize the potential of oligonucleotide therapeutics for prevalent diseases and improved market acceptance.

100+ Industry Experts | 3 Interactive Workshops | 20% Off Group Discounts | Data-Driven Case Studies

Brochure: https://go.evvnt.com/2426493-2?pid=91 

Prices:

Drug Developer Pricing - Conference + Full Workshop Day: USD 4197.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Service Provider Pricing - Conference + Full Workshop Day: USD 5097.00,

Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Angela Tsai, Manager, External QA Operations, Sanofi, Armin Delavari, Senior Scientist, Biogen, Arnold McAuley, Senior Principal Scientist, Amgen, Bao Cai, Executive Director, Research Manufacturing, Sarepta Therapeutics, Carter Cooperman, Research Associate, Ionis Pharmaceuticals, Debasis Patra, Vice President, Senior Director and Head Of Chemistry, Manufacturing and Controls, OliX Pharmaceuticals, George Bou-Assaf, Associate Director, Biogen, Hagen Cramer, Chief Technology Officer, QurAlis, Huijun Tian, Director, Analytical Development and Quality Control, QurAlis, Isaiah Cedillo, Executive Director, Manufacturing and Operations, Ionis Pharmaceuticals, Janine Tom, Senior Principal Scientist, Amgen, Judy Carmody, Founder and Principal Consultant, Carmody Quality Solutions, Matthew McQueen, Associate Director, Avidity Biosciences, Mona Bill, Senior Scientist, Analytical Chemistry, Silence Therapeutics, Naresh badgujar, Associate Principal Scientist, AstraZeneca, Satya Kuchimanchi, Senior Vice President, CAMP4 Therapeutics, Tao Wei, Associate Director - Ribonucleic Acid Process Development, Sarepta Therapeutics, Xiao Zhou, Scientist, Biogen